Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to Mirum Pharmaceuticals, Inc. First Quarter 2026 earnings conference call. My name is Tracy, and I will be your operator today.
Mirum Pharmaceuticals Inc. (MIRM)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 70,000,000 | $209,440,280 | 2.47% | ||
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,584,727 | $146,397,080 | +6% | 4.66% |
| 3. | Tang Capital Management Kevin C. Tang | 1,236,027 | $114,184,174 | 5.8% | |
| 4. | Citadel Investment Group Ken Griffin | 1,052,048 | $97,188,194 | +26% | 0.02% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 811,294 | $74,947,340 | +7% | 4.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $68.48 | 131,425 | $8,999,984.00 | 459,010 | 2026-01-23 | Filing | |
| $43.93 | 21 | $922.61 | 168,672 | 2025-03-17 | Filing | |
| $44.11 | 528 | $23,291.40 | 168,651 | 2025-03-14 | Filing | |
| $43.77 | 963 | $42,155.13 | 168,123 | 2025-03-11 | Filing | |
| $43.37 | 577 | $25,023.34 | 167,160 | 2025-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $96.90 | 2,000 | $193,800.00 | 0 | 2026-04-15 | Filing | |
| $91.98 | 7,287 | $670,242.96 | 49,788 | 2026-03-16 | Filing | |
| $91.98 | 7,287 | $670,242.96 | 18,864 | 2026-03-16 | Filing | |
| $90.76 | 2,000 | $181,520.00 | 0 | 2026-03-16 | Filing | |
| $91.98 | 16,515 | $1,519,015.02 | 40,272 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,679,684 | $709,449,208 | 18.25% | |
| 2. | 6,789,239 | $627,298,611 | 0.31% | |
| 3. | 3,846,530 | $355,342,442 | 0.01% | |
| 4. | 2,414,776 | $223,077,007 | 0% | |
| 5. | 1,965,375 | $181,561,365 | 0.01% |
News See All
15 Most Promising Stocks Under $100 to Buy
On March 12, Roger Ferguson, former Fed Vice Chair, joined 'Closing Bell' on CNBC to discuss what to expect from the Federal Reserve next week.
H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why?
On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating.
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Should You Invest in Mirum Pharmaceuticals (MIRM)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter.
Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Baird reiterated its Outperform rating on Mirum Pharmaceuticals Inc.
Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition
Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the high short interest stocks to buy right now.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
Hedge Fund Resource Center